Journal
INTERNATIONAL JOURNAL OF CANCER
Volume 150, Issue 2, Pages 317-326Publisher
WILEY
DOI: 10.1002/ijc.33800
Keywords
advanced melanoma; anti-PD-1; discontinuation; immunotherapy; real-world
Categories
Funding
- Dutch Melanoma Treatment Registry (DMTR)
- governmental organisation The Netherlands Organization for Health Research and Development (ZonMW) [836002002]
- Bristol-Myers Squibb
- Merck Sharpe Dohme
- Novartis
- Roche Pharma
- DMTR
Ask authors/readers for more resources
There is no consensus on the optimal treatment duration of anti-PD-1 for advanced melanoma. Our study aimed to gain insight into the outcomes of anti-PD-1 discontinuation, the association of treatment duration with progression, and re-treatment with anti-PD-1 in relapsing patients. The results showed that patients with partial or complete response to anti-PD-1 treatment can have durable remissions even after discontinuation.
There is no consensus on the optimal treatment duration of anti-PD-1 for advanced melanoma. The aim of our study was to gain insight into the outcomes of anti-PD-1 discontinuation, the association of treatment duration with progression and anti-PD-1 re-treatment in relapsing patients. Analyses were performed on advanced melanoma patients in the Netherlands who discontinued first-line anti-PD-1 monotherapy in the absence of progressive disease (n = 324). Survival was estimated after anti-PD-1 discontinuation and with a Cox model the association of treatment duration with progression was assessed. At the time of anti-PD-1 discontinuation, 90 (28%) patients had a complete response (CR), 190 (59%) a partial response (PR) and 44 (14%) stable disease (SD). Median treatment duration for patients with CR, PR and SD was 11.2, 11.5 and 7.2 months, respectively. The 24-month progression-free survival and overall survival probabilities for patients with a CR, PR and SD were, respectively, 64% and 88%, 53% and 82%, 31% and 64%. Survival outcomes of patients with a PR and CR were similar when anti-PD-1 discontinuation was not due to adverse events. Having a PR at anti-PD-1 discontinuation and longer time to first response were associated with progression [hazard ratio (HR) = 1.81 (95% confidence interval, CI = 1.11-2.97) and HR = 1.10 (95% CI = 1.02-1.19; per month increase)]. In 17 of the 27 anti-PD-1 re-treated patients (63%), a response was observed. Advanced melanoma patients can have durable remissions after (elective) anti-PD-1 discontinuation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available